DAC group raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-26. Anything still debated is marked as such rather than presented as settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
== History == Chlordiazepoxide (initially called methaminodiazepoxide) was the first benzodiazepine to be synthesized in the mid-1950s. The synthesis was derived from work on a class of dyes, quinazoline-3-oxides. It was discovered by accident when in 1957 tests revealed that the compound had hypnotic, anxiolytic, and muscle relaxant effects. "The story of the chemical development of Librium and Valium was told by Sternbach. The serendipity involved in the invention of this class of compounds was matched by the trials and errors of the pharmacologists in the discovery of the tranquilizing activity of the benzodiazepines. The discovery of Librium in 1957 was due largely to the dedicated work and observational ability of a gifted technician, Beryl Kappell. For some seven years she had been screening compounds by simple animal tests for muscle relaxant activity using Myanesin as a standard and then meprobamate and chlorpromazine when they became available. All compounds submitted by the chemical staff for central nervous activity were screened. It was this battery of tests that picked out RO 5-0690 (Librium, chlordiazepoxide) as being similar but more potent than meprobamate." Three years later chlordiazepoxide was marketed as a therapeutic benzodiazepine medication under the brand name Librium. Following chlordiazepoxide, in 1963 diazepam hit the market under the brand name Valium—and was followed by many further benzodiazepine compounds over the subsequent years and decades. In 1959 it was used by over 2,000 physicians and more than 20,000 patients.
U+039B Λ GREEK CAPITAL LETTER LAMDA (Λ) U+03BB λ GREEK SMALL LETTER LAMDA (λ) U+1D27 ᴧ GREEK LETTER SMALL CAPITAL LAMDA U+2C96 Ⲗ COPTIC CAPITAL LETTER LAULA U+2C97 ⲗ COPTIC SMALL LETTER LAULA U+A7DA LATIN CAPITAL LETTER LAMBDA U+A7DB LATIN SMALL LETTER LAMBDA U+1038D 𐎍 UGARITIC LETTER LAMDA U+1D6B2 𝚲 MATHEMATICAL BOLD CAPITAL LAMDA U+1D6CC 𝛌 MATHEMATICAL BOLD SMALL LAMDA U+1D6EC 𝛬 MATHEMATICAL ITALIC CAPITAL LAMDA U+1D706 𝜆 MATHEMATICAL ITALIC SMALL LAMDA U+1D726 𝜦 MATHEMATICAL BOLD ITALIC CAPITAL LAMDA U+1D740 𝝀 MATHEMATICAL BOLD ITALIC SMALL LAMDA U+1D760 𝝠 MATHEMATICAL SANS-SERIF BOLD CAPITAL LAMDA U+1D77A 𝝺 MATHEMATICAL SANS-SERIF BOLD SMALL LAMDA U+1D79A 𝞚 MATHEMATICAL SANS-SERIF BOLD ITALIC CAPITAL LAMDA U+1D7B4 𝞴 MATHEMATICAL SANS-SERIF BOLD ITALIC SMALL LAMDA
On 20 February 1990 the Volkskammer passed a new electoral law, reducing it in size to 400 members elected via party-list proportional representation, with no electoral threshold. Joint lists between parties were allowed, and a number of parties formed alliances for the election, including the Association of Free Democrats, Alliance 90, and an alliance between the Green Party and Independent Women's Association. Seats were calculated nationally using the largest remainder method, and distributed in multi-member constituencies corresponding to the fifteen Bezirke.
=== Nictitating membrane === Some mammals, such as cats, camels, polar bears, seals and aardvarks, have a full translucent third eyelid called a nictitating membrane, while others have a vestigial nictitating membrane. The membrane works to protect and moisten the eyelid while maintaining visibility. It also contributes to the aqueous portion of the tear film and possibly immunoglobulins. Humans and some primates have a much smaller nictitating membrane; this may be because they do not capture prey or root vegetation with their teeth, so that there is no evolutionary advantage of the third eyelid.
=== Introduction of nylon blends === As pure nylon hosiery was sold in a wider market, problems became apparent. Nylon stockings were found to be fragile, in the sense that the thread often tended to unravel lengthwise, creating 'runs'. People also reported that pure nylon textiles could be uncomfortable due to nylon's lack of absorbency. Moisture stayed inside the fabric near the skin under hot or moist conditions instead of being "wicked" away. Nylon fabric could also be itchy and tended to cling and sometimes spark as a result of static electrical charge built up by friction. Also, under some conditions, nylon could degrade, perforating or shredding stockings. Scientists explained this as acid hydrolysis resulting from air pollution, attributing it to London smog in 1952, as well as poor air quality in New York and Los Angeles. The solution found to problems with pure nylon fabric was to blend nylon with other existing fibers or polymers such as cotton, polyester, and spandex. This led to the development of a wide array of blended fabrics. The new nylon blends retained the desirable properties of nylon (elasticity, durability, ability to be dyed) and kept clothes prices low and affordable. As of 1950, the New York Quartermaster Procurement Agency (NYQMPA), which developed and tested textiles for the Army and Navy, had committed to developing a wool-nylon blend. They were not the only ones to introduce blends of both natural and synthetic fibers. America's Textile Reporter referred to 1951 as the "Year of the blending of the fibres".
Sources: en.wikipedia.org
Serpin A12 (OL-64, Vaspin, Visceral adipose-specific serpin, Ser A12) is a glycoprotein that is a class A member of the serine protease inhibitor (serpin) family. In humans, Serpin A12 is encoded by the SERPINA12 gene. First discovered in 2005, Serpin A12 was highly expressed in white adipose tissue of Otsuka Long Evans Tokushima Fatty Rats at the same time that the rats' obesity and insulin plasma levels reached a peak, at around 30 weeks old. Eventually, it was found to be expressed in visceral and subcutaneous adipose tissue of obese humans, leading the protein to be linked with obesity, glucose metabolism, and insulin resistance.
== Production == Cyanocobalamin is commercially prepared by bacterial fermentation. Fermentation by a variety of microorganisms yields a mixture of methylcobalamin, hydroxocobalamin and adenosylcobalamin. These compounds are converted to cyanocobalamin by addition of potassium cyanide in the presence of sodium nitrite and heat. Since multiple species of Propionibacterium produce no exotoxins or endotoxins and have been granted GRAS status (generally regarded as safe) by the United States Food and Drug Administration, they are the preferred bacterial fermentation organisms for vitamin B12 production. Historically, the physiological form was initially thought to be cyanocobalamin. This was because hydroxocobalamin produced by bacteria was changed to cyanocobalamin during purification in activated charcoal columns after separation from the bacterial cultures (because cyanide is naturally present in activated charcoal). Cyanocobalamin is the form in most pharmaceutical preparations because adding cyanide stabilizes the molecule. The total world production of vitamin B12, by four companies (the French Sanofi-Aventis and three Chinese companies) in 2008 was 35 tonnes.
=== Lipids === Source: The lipid tail is essential for enabling lipid membrane insertion and retention but also for giving the construct amphiphilic characteristics that enable hydrophilic surface coating (due to formation of bilipid layers). Different membrane lipids that can be used to create FSLs have different membrane physiochemical characteristics and thus can affect biological function of the FSL. Lipids in FSL Kode constructs include:
When this was made illegal, the cathinone was modified, and the new products were sold by the Israeli company Neorganics. The products had names such as Neodoves pills, but the range was discontinued in January 2008 after the Israeli government made mephedrone illegal. The Psychonaut Research Project, an EU organisation that searches the internet for information regarding new drugs, first identified mephedrone in 2008. Their research suggested the drug first became available to purchase on the internet in 2007, made available through British contacts, contact unknown, when it was also discussed on internet forums. Mephedrone was first seized in France in May 2007, after police sent a tablet they assumed to be ecstasy to be analysed, with the discovery published in a paper titled "Is 4-methylephedrone, an "Ecstasy" of the twenty-first century?" Mephedrone was reported as having been sold as ecstasy in the Australian city of Cairns, along with ethylcathinone, in 2008. An annual survey of regular ecstasy users in Australia in 2010 found 21% of those surveyed had used mephedrone, with 17% having done so in the previous six months. The price they paid per gram varied from A$16 to $320. Europol noted they became aware of it in 2008, after it was found in Denmark, Finland and the UK. The Drug Enforcement Administration noted it was present in the United States in July 2009. By May 2010, mephedrone had been detected in all 22 EU member states that reported to Europol, as well as in Croatia and Norway.
Imaging technologies are often essential to medical diagnosis, and are typically the most complex equipment found in a hospital including: fluoroscopy, magnetic resonance imaging (MRI), nuclear medicine, positron emission tomography (PET), PET-CT scans, projection radiography such as X-rays and CT scans, tomography, ultrasound, optical microscopy, and electron microscopy. An implant is a kind of medical device made to replace and act as a missing biological structure (as compared with a transplant, which indicates transplanted biomedical tissue). The surface of implants that contact the body might be made of a biomedical material such as titanium, silicone or apatite depending on what is the most functional. In some cases, implants contain electronics, e.g. artificial pacemakers and cochlear implants. Some implants are bioactive, such as subcutaneous drug delivery devices in the form of implantable pills or drug-eluting stents.
Sources: en.wikipedia.org
== Career == Akagha attended Southern Methodist University in Dallas, Texas, where she majored in theatre. In the early 2010s, she acted in theatrical productions in California. In 2010, she played Tiger Lily in the Pacific Conservatory of the Performing Arts's production of Peter Pan. In 2011, she acted alongside Brendan Cataldo in Leo Cortez's play, Acting Out, at the Alisal Center for the Fine Arts. In 2012, Akagha began playing the leads in various short films and making guest appearances in television series. She appeared in one-off episodes in the series Men at Work, Nashville and 2 Broke Girls. Akagha started voice acting in video games around 2016, first voicing the character "Plastic" in the game Mirror's Edge: Catalyst. In 2017, she was a voice actor for Wolfenstein II: The New Colossus, in which she provided voices for characters Barbara Casey, Zena Woodard, and Angela Cummings. In 2018, she began appearing in Marvel's Runaways television series as Tamar, a recurring, supporting role. She provided the voice for the superheroine Bumblebee in the animated series Teen Titans Go!. Bumblebee initially appeared in the show's fifth season in the episode "Forest Pirates", which aired in 2019. Akagha voiced the main character, Alyx Vance, in the virtual reality game Half-Life: Alyx. The character was first introduced in the game Half-Life 2 in 2004, being originally played by Merle Dandridge. A new actor was chosen for Alyx Vance partially due to the character's younger age and the "time gap" between this and the previous game.
Additionally, the FDA has raised concerns over the lack of data to determine if the long-acting once-weekly version of exenatide (but not the twice-daily form of exenatide) may increase thyroid cancer risk. This concern comes out of observing a very small but nevertheless increased risk of thyroid cancer in rodents that was observed for another drug (liraglutide) that is in the same class as exenatide. The data available for exenatide showed less of a risk towards thyroid cancer than liraglutide, but to better quantify the risk the FDA has required Amylin to conduct additional rodent studies to better identify the thyroid issue. The approved form of the once weekly exenatide [Bydureon] has a black box warning discussing the thyroid issue. Eli Lilly has reported they have not seen a link in humans, but that it cannot be ruled out. Eli Lilly has stated the drug causes an increase in thyroid problems in rats given high doses. In March 2013, the FDA issued a Drug Safety Communication announcing investigations into incretin mimetics due to findings by academic researchers. A few weeks later, the European Medicines Agency launched a similar investigation into GLP-1 agonists and DPP-4 inhibitors.
Metabolic intermediates are compounds produced during the conversion of substrates (starting molecules) into final products in biochemical reactions within cells. Although these intermediates are of relatively minor direct importance to cellular function, they can play important roles in the allosteric regulation of enzymes, glycolysis, the citric acid cycle, and amino acid synthesis. Metabolic pathways consist of a series of enzymatically catalyzed reactions where each step transforms a substrate into a product that serves as the substrate for the next reaction. Metabolic intermediates are compounds that form during these steps, and they are neither the starting substrate nor the final product of the pathway. These intermediates are crucial because they allow for regulation, energy storage, and extraction of chemical energy in a controlled manner.
Ketamine principally acts as a pore blocker of the NMDA receptor, an ionotropic glutamate receptor. The S-(+) and R-(–) stereoisomers of ketamine bind to the dizocilpine site of the NMDA receptor with different affinities, the former showing approximately 3- to 4-fold greater affinity for the receptor than the latter. As a result, the S isomer is a more potent anesthetic and analgesic than its R counterpart. Ketamine may interact with and inhibit the NMDAR via another allosteric site on the receptor. With a couple of exceptions, ketamine's actions at other receptors are far weaker than its antagonism of the NMDA receptor (see the activity table to the right). Although ketamine is a very weak ligand of the monoamine transporters (Ki > 60 μM), it has been suggested that it may interact with allosteric sites on the monoamine transporters to produce monoamine reuptake inhibition. However, no functional inhibition (IC50) of the human monoamine transporters has been observed with ketamine or its metabolites at concentrations of up to 10,000 nM. Moreover, animal studies and at least three human case reports have found no interaction between ketamine and the monoamine oxidase inhibitor (MAOI) tranylcypromine, which is of importance as the combination of a monoamine reuptake inhibitor with an MAOI can produce severe toxicity such as serotonin syndrome or hypertensive crisis. Collectively, these findings shed doubt on the involvement of monoamine reuptake inhibition in the effects of ketamine in humans.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.